BioMarin Pharmaceutical (BMRN) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.
Analysts polled by FactSet expected $0.74.
Revenue for the quarter ended Dec. 31 was $747.3 million, compared with $646.2 million a year earlier.
Analysts polled by FactSet expected $712.3 million.
For 2025, the company is projecting non-GAAP EPS of $4.20 to $4.40 on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet are looking for $4.15 and $3.10 billion, respectively.
BioMarin shares recently were up 8.2% in Wednesday's after-hours session.
Price: 71.00, Change: +5.39, Percent Change: +8.22
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。